MARLBOROUGH, Mass., June 1, 2026
SCIEX, a Danaher company and a global leader in life science analytical technologies, announced major advancements across its ZenoTOF accurate mass spectrometry platform at the ASMS 2026 conference. The latest enhancements include the launch of SCIEX OS 5.0 software, expanded instrument compatibility, and new collaborations with leading software and technology providers. These innovations are designed to simplify complex omics workflows while helping researchers generate deeper biological insights across proteomics, metabolomics, lipidomics, biomarker discovery, and translational research. The company believes the expanded ZenoTOF ecosystem will provide scientists with a more flexible and integrated platform for addressing increasingly complex research challenges in biotechnology and pharmaceutical development.
AI-Powered Software Enhances Laboratory Productivity
A key component of the platform expansion is the introduction of SCIEX OS 5.0, which delivers several advanced features designed to improve laboratory efficiency and streamline data analysis. New capabilities include Central Metrics Tracker, Central Monitoring, Reporter Template Creator, an AI-enabled “helpme” assistant, and AI-powered Calculated Columns that simplify data interpretation. SCIEX also introduced ZT Scan DIA 3.0, a next-generation acquisition technology that combines the comprehensive coverage of data-independent acquisition with narrower Q1 isolation windows. This enables researchers to optimize sensitivity, selectivity, and throughput according to specific experimental requirements. The technology is expected to support scalable proteomics and robust metabolomics workflows while reducing overall workflow complexity and improving data quality.
Enhanced Instrument Integration Supports Advanced Omics Research
SCIEX has expanded the flexibility of the ZenoTOF platform through new hardware integrations and workflow enhancements. The integration of the Echo® MS+ system with the ZenoTOF 8600 creates one of the industry’s highest-throughput accurate mass spectrometry platforms, capable of processing up to one sample per second. This advancement offers improved sensitivity for high-throughput screening applications while reducing consumable costs and workflow complexity. The company also highlighted its collaboration with Trajan Scientific and Medical to support advanced HDX-MS applications, enabling researchers to gain deeper insights into protein structure and molecular interactions. Additional compatibility enhancements with Evosep, IonOpticks, and Aurora XS columns further strengthen the platform’s ability to support next-generation proteomics research, combining high sensitivity, robustness, and throughput within a unified workflow.
Advertisement
Strategic Collaborations Expand Biomarker Discovery Capabilities
SCIEX also announced several strategic software collaborations designed to improve biomarker discovery and data analysis capabilities. Integration with BSI’s AI-powered PEAKS software enables researchers to identify, quantify, and validate biomarkers within a single workflow, reducing the fragmentation that often exists between discovery and targeted quantitation studies. The collaboration with MS-DIAL allows scientists to utilize ZT Scan DIA 3.0 data for advanced metabolomics and lipidomics research, supporting the identification of novel biomarkers and biological pathways. In addition, SCIEX has partnered with MZIO to bring full SCIEX data compatibility to the mzMine platform, enabling seamless integration into existing metabolomics and small-molecule analysis pipelines. According to SCIEX leadership, these developments represent a significant step toward creating a fully connected omics ecosystem that supports scientific innovation across the drug discovery and translational research continuum.
Positioning ZenoTOF as a Comprehensive Omics Platform
The latest ZenoTOF advancements underscore SCIEX’s broader strategy of delivering an integrated analytical platform capable of evolving alongside scientific needs. By combining artificial intelligence, advanced mass spectrometry, high-throughput screening technologies, and strategic software partnerships, the company aims to empower researchers with faster, more reliable, and more actionable insights. As the demand for precision medicine, biomarker-driven drug development, and systems biology continues to grow, SCIEX believes its expanding ZenoTOF ecosystem will play a critical role in helping researchers accelerate discoveries and improve outcomes across the biotechnology and pharmaceutical industries.
Source: SCIEX press release
